U
BCRX icon

UBS’s BioCryst Pharmaceuticals BCRX Stock Holding History

UBS’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-4,600
Closed -$35K – 10421
2013
Q4 		$35K Buy
4,600
+1,600
+53% +$10.1K ﹤0.01% 7428
2013
Q3 		$22K Sell
3,000
-2,000
-40% -$10.1K ﹤0.01% 7929
2013
Q2 		$8K Buy
+5,000
New +$8.63K ﹤0.01% 8824

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

UBS's BCRX Position: Q3 2014 in Review

UBS reduced its BioCryst Pharmaceuticals (BCRX) stake by 0.58% in Q3 2014, selling an estimated $4.9K and leaving 68,344 shares worth $668K. The position accounts for ﹤0.01% of the portfolio, ranked #4001.

UBS first reported a position in BCRX in Q2 2013 and has held it in 6 quarters since. The position peaked at $1.75M in Q1 2014. 102 funds tracked by Wall St. Rank hold BCRX as of Q3 2014.

  • UBS held 68,344 shares of BioCryst Pharmaceuticals worth $668K as of Q3 2014.
  • UBS sold 400 BioCryst Pharmaceuticals shares in Q3 2014, an estimated $4.9K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of UBS's portfolio in Q3 2014, its #4001 holding.
  • UBS first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
  • UBS's BioCryst Pharmaceuticals position peaked at $1.75M in Q1 2014.
  • 102 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.